Skip to main content
SpringerLink
Log in

Chronic Urticaria

Aetiology, Management and Current and Future Treatment Options

  • Review Article
  • Published:
Drugs Aims and scope Submit manuscript

Abstract

Chronic urticaria is a common condition that can be very disabling when severe. A cause for chronic idiopathic urticaria (CIU) is only infrequently identified. Potential causes include reactions to food and drugs, infections (rarely) and, apart from an increased incidence of thyroid disease, uncomplicated urticaria is not usually associated with underlying systemic disease or malignancy. About one-third of patients with CIU have circulating functional autoantibodies against the high affinity IgE receptor or against IgE, although it is not known why such antibodies are produced, or how the presence of such antibodies alters the course of the disease or response to treatment. There are only a few publications relating to childhood urticaria, but it is probably similar to the adult form, except that adult urticaria is more common.

The diagnosis is based on patient history and it is vital to spend time documenting this in detail. Extensive laboratory tests are not required in the vast majority of patients. Chronic urticaria resolves spontaneously in 30–55% of patients within 5 years, but it can persist for many years.

Treatment is aimed firstly at avoiding underlying causative or exacerbating factors. Histamine H1 receptor antagonists remain the mainstay of oral treatment for all forms of urticaria. The newer low-sedating antihistamines desloratadine, fexofenadine, levocetirizine and mizolastine should be tried first. Sedating antihistamines have more adverse effects but are useful if symptoms are causing sleep disturbance. Low-dose dopexin is effective and especially suitable for patients with associated depression. There is controversy as to whether the addition of an histamine H2 receptor antagonist or a leukotriene antagonist is helpful. For CIU, second-line agents include ciclosporin (cyclosporine) [which is effective in approximately 75% of patients], short courses of oral corticosteroids, intravenous immunoglobulins and plasmapheresis, although the last two were found to be beneficial in small trials only. Treatments for CIU with only limited or anecdotal supportive evidence include sulphasalazine, methotrexate, stanazol, rofecoxib and cyclophosphamide. The efficacy of photo(chemo)therapy is controversial.

Physical urticarias may respond to H1 receptor antagonists, although in delayed pressure urticaria, and cold, solar and aquagenic urticaria, the response may be disappointing. Second-line agents for physical urticarias vary depending on the urticaria and most have limited supportive evidence.

The potential for spontaneous resolution, the variation in the disease activity and the unpredictable nature of the disease makes the efficacy of treatments difficult to assess.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Table I

Similar content being viewed by others

Notes

  1. The use of trade names is for product identification purposes only and does not imply endorsement.

References

  1. Zuberbier T, Greaves MW, Juhlin L, et al. Definition, classification, and routine diagnosis of urticaria: a consensus report. J Investig Dermatol Symp Proc 2001; 6: 123–7

    Article  PubMed  CAS  Google Scholar 

  2. Sabroe RA, Kobza-Black A. Angiotensin converting enzyme (ACE) inhibitors and angio-oedema. Br J Dermatol 1997; 136: 153–8

    Article  PubMed  CAS  Google Scholar 

  3. Kobza Black A, Lawlor F, Greaves MW. Consensus meeting on the definition of physical urticarias and urticarial vasculitis. Clin Exp Dermatol 1996; 21: 424–6

    Article  Google Scholar 

  4. Niimi N, Francis DM, Kermani F, et al. Dermal mast cell activation by autoantibodies against the high affinity IgE receptor in chronic urticaria. J Invest Dermatol 1996; 106: 1001–6

    Article  PubMed  CAS  Google Scholar 

  5. Hide M, Francis DM, Grattan CEH, et al. Autoantibodies against the high-affinity IgE receptor as a cause of histamine release in chronic urticaria. N Engl J Med 1993; 328: 1599–604

    Article  PubMed  CAS  Google Scholar 

  6. Ferrer M, Kinèt J-P, Kaplan AP. Comparative studies of functional and binding assays for IgG anti-FceRIa (α-subunit) in chronic urticaria. J Allergy Clin Immunol 1998; 101: 672–6

    Article  PubMed  CAS  Google Scholar 

  7. Fiebiger E, Maurer D, Holub H, et al. Serum IgG autoantibodies directed against the a chain of FceRI: a selective marker and pathogenetic factor for a distinct subset of chronic urticaria patients? J Clin Invest 1995; 96: 2606–12

    Article  PubMed  CAS  Google Scholar 

  8. Fiebiger E, Hammerschmid F, Stingl G, et al. Anti-FceRIa autoantibodies in autoimmune-mediated disorders: identification of a structure-function relationship. J Clin Invest 1998; 101(1): 243–51

    Article  PubMed  CAS  Google Scholar 

  9. Swinny B. The atopic factor in urticaria. South Med J 1941; 34(8): 855–87

    Article  Google Scholar 

  10. McKee WD. The incidence and familial occurrence of allergy. J Allergy 1966; 38(4): 226–35

    Article  PubMed  CAS  Google Scholar 

  11. Schafer T, Ring J. Epidemiology of urticaria. Basel: Karger, 1993

    Google Scholar 

  12. Paul E, Greilich KD, Dominante G. Epidemiology of urticaria. Monogr Allergy 1987; 21: 87–115

    PubMed  CAS  Google Scholar 

  13. Margolis CF, Nisi R. Urticaria in a family practice. J Fam Pract 1985; 20(1): 57–64

    PubMed  CAS  Google Scholar 

  14. Paul E, Greilich KD. Zur Epidemiologie der Urtikariaer-krankungen. Hautarzt 1991; 42(6): 366–75

    PubMed  CAS  Google Scholar 

  15. Henz BM. Physical urticaria. In: Henz BM, Zuberbier T, Grabbe J, et al., editors. Urticaria: clinical, diagnostic and therapeutic aspects. Berlin: Springer Verlag, 1998: 55–89

    Google Scholar 

  16. Kontou-Fili K, Borici-Mazi R, Kapp A, et al. Physical urticaria: classification and diagnostic guidelines: an EAACI position paper. Allergy 1997; 52(5): 504–13

    Article  PubMed  CAS  Google Scholar 

  17. Zuberbier T, Althaus C, Chantraine-Hess S, et al. Prevalence of cholinergic urticaria in young adults. J Am Acad Dermatol 1994; 31(6): 978–81

    Article  PubMed  CAS  Google Scholar 

  18. Neittaanmaki H. Cold urticaria: clinical findings in 220 patients. J Am Acad Dermatol 1985; 13(4): 636–44

    Article  PubMed  CAS  Google Scholar 

  19. Wanderer AA. Cold urticaria syndromes: historical background, diagnostic classification, clinical and laboratory characteristics, pathogenesis, and management. J Allergy Clin Immunol 1990; 85(6): 965–81

    Article  PubMed  CAS  Google Scholar 

  20. Sullivan TJ. Diagnosis and management of drug allergy. In: Schocket AL, editor. Clinical management of urticaria and anaphylaxis. New York: Marcel Dekker Inc., 1993: 69–98

    Google Scholar 

  21. Kozel MM, Bossuyt PM, Mekkes JR, et al. Laboratory tests and identified diagnoses in patients with physical and chronic urticaria and angioedema: a systematic review. J Am Acad Dermatol 2003; 48(3): 409–16

    Article  PubMed  Google Scholar 

  22. Pacor ML, Di Lorenzo G, Biasi D, et al. Safety of rofecoxib in subjects with a history of adverse cutaneous reactions to aspirin and/or non-steroidal anti-inflammatory drugs. Clin Exp Allergy 2002; 32(3): 397–400

    Article  PubMed  CAS  Google Scholar 

  23. Perrone MR, Artesani MC, Viola M, et al. Tolerability of rofecoxib in patients with adverse reactions to nonsteroidal anti-inflammatory drugs: a study of 216 patients and literature review. Int Arch Allergy Immunol 2003; 132(1): 82–6

    Article  PubMed  CAS  Google Scholar 

  24. Zembowicz A, Mastalerz L, Setkowicz M, et al. Safety of cyclooxygenase 2 inhibitors and increased leukotriene synthesis in chronic idiopathic urticaria with sensitivity to nonsteroidal anti-inflammatory drugs. Arch Dermatol 2003; 139(12): 1577–82

    Article  PubMed  CAS  Google Scholar 

  25. Henz BM, Zuberbier T. Causes of urticaria. In: Henz BM, Zuberbier T, Grabbe J, et al., editors. Urticaria: clinical, diagnostic and therapeutic aspects. Berlin: Springer Verlag, 1998: 18–38

    Google Scholar 

  26. Ortolani C, Pastorello E, Ispano M, et al. Food allergy diagnosis protocol. Allerg Immunol (Paris) 1988; 20(2): 48–50

    CAS  Google Scholar 

  27. Zuberbier T, Chantraine-Hess S, Hartmann K, et al. Pseudoal-lergen-free diet in the treatment of chronic urticaria: a prospective study. Acta Derm Venereol 1995; 75(6): 484–7

    PubMed  CAS  Google Scholar 

  28. Champion RH. Urticaria: then and now. Br J Dermatol 1988; 119(4): 427–36

    Article  PubMed  CAS  Google Scholar 

  29. Schnyder B, Helbling A, Pichler WJ. Chronic idiopathic urticaria: natural course and association with Helicobacter pylori infection. Int Arch Allergy Immunol 1999; 119(1): 60–3

    Article  PubMed  CAS  Google Scholar 

  30. Valsecchi R, Pigatto P. Chronic urticaria and Helicobacter pylori. Acta Derm Venereol 1998; 78(6): 440–2

    Article  PubMed  CAS  Google Scholar 

  31. Hook-Nikanne J, Varjonen E, Harvima RJ, et al. Is, Helicobacter pylori infection associated with chronic urticaria? Acta Derm Venereol 2000; 80(6): 425–6

    Article  PubMed  CAS  Google Scholar 

  32. Kanazawa K, Yaoita H, Tsuda F, et al. Hepatitis C virus infection in patients with urticaria. J Am Acad Dermatol 1996; 35: 195–8

    Article  PubMed  CAS  Google Scholar 

  33. Cribier BJ, Santinelli F, Schmitt C, et al. Chronic urticaria is not significantly associated with hepatitis C or hepatitis G infection: a case-control study. Arch Dermatol 1999; 135(11): 1335–9

    Article  PubMed  CAS  Google Scholar 

  34. Finn AF, Levy AL, Banov CH. Autoimmune thyroid antibodies and thyroid function tests in chronic urticaria and angioedema [abstract]. J Allergy Clin Immunol 1997; 99: S334

    Google Scholar 

  35. Leznoff A, Sussman GL. Syndrome of idiopathic chronic urticaria and angioedema with thyroid autoimmunity: a study of 90 patients. J Allergy Clin Immunol 1989; 84: 66–71

    Article  PubMed  CAS  Google Scholar 

  36. Sigurgeirsson B. Skin disease and malignancy: an epidemiological study. Acta Derm Venereol Suppl (Stockh) 1992; 178: 1–110

    CAS  Google Scholar 

  37. Geha RS, Quinti I, Austen KF, et al. Acquired Cl-inhibitor deficiency associated with antiidiotypic antibody to monoclonal immunoglobulins. N Engl J Med 1985; 312(9): 534–40

    Article  PubMed  CAS  Google Scholar 

  38. Grattan CEH, Wallington TB, Warin RP, et al. A serological mediator in chronic idiopathic urticaria: a clinical, immunological and histological evaluation. Br J Dermatol 1986; 114: 583–90

    Article  PubMed  CAS  Google Scholar 

  39. Sabroe RA, Grattan CEH, Francis DM, et al. The autologous serum skin test: a screening test for autoantibodies in chronic idiopathic urticaria. Br J Dermatol 1999; 140: 446–52

    Article  PubMed  CAS  Google Scholar 

  40. Sabroe RA, Fiebiger E, Francis DM, et al. Classification of anti-FceRI and anti-IgE autoantibodies in chronic idiopathic urticaria and correlation with disease severity. J Allergy Clin Immunol 2002; 110(3): 492–9

    Article  PubMed  CAS  Google Scholar 

  41. O’Donnell BF, O’Neill CM, Francis DM, et al. Human leucocyte antigen class II associations in chronic idiopathic urticaria. Br J Dermatol 1999; 140: 853–8

    Article  PubMed  Google Scholar 

  42. O’Donnell BF, Swana GT, Kobza Black A, et al. Organ and non organ specific auto-immunity in chronic urticaria [abstract]. Br J Dermatol 1995; 133 Suppl. 45: 42

    Google Scholar 

  43. Rottem M. Chronic urticaria and autoimmune thyroid disease: is there a link? Autoimmun Rev 2003; 2(2): 69–72

    Article  PubMed  Google Scholar 

  44. Sabroe RA, Seed PT, Francis DM, et al. Chronic idiopathic urticaria: comparison of the clinical features of patients with and without anti-FcεRI or anti-IgE autoantibodies. J Am Acad Dermatol 1999; 40: 443–50

    Article  PubMed  CAS  Google Scholar 

  45. Nettis E, Dambra P, D’Oronzio L, et al. Reactivity to autologous serum skin test and clinical features in chronic idiopathic urticaria. Clin Exp Dermatol 2002; 27(1): 29–31

    Article  PubMed  CAS  Google Scholar 

  46. Sabroe RA, Poon E, Orchard GE, et al. Cutaneous inflammatory cell infiltrate in chronic idiopathic urticaria: comparison of patients with and without anti-FcεRI or anti-IgE autoantibodies. J Allergy Clin Immunol 1999; 103 (3 Pt 1): 484–93

    Article  PubMed  CAS  Google Scholar 

  47. Balaban J. Medicaments as the possible cause of urticaria in children. Acta Dermatovenerol Croat 2002; 10(3): 155–9

    PubMed  Google Scholar 

  48. Kauppinen K, Juntunen K, Lanki H. Urticaria in children: retrospective evaluation and follow-up. Allergy 1984; 39(6): 469–72

    Article  PubMed  CAS  Google Scholar 

  49. Tuchinda M, Srimaruta N, Habanananda S, et al. Urticaria in Thai children. Asian Pac J Allergy Immunol 1986; 4(1): 41–5

    PubMed  CAS  Google Scholar 

  50. Sorensen HT, Christensen B, Kjaerulff E. A two-year follow-up of children with urticaria in general practice. Scand J Prim Health Care 1987; 5(1): 24–6

    Article  PubMed  CAS  Google Scholar 

  51. Moreno MV, Gonzalez de la Cuesta C, Oehling A. Contribution to the etiopathogenesis of urticaria in children. Allergol Immunopathol (Madr) 1988; 16(4): 225–30

    CAS  Google Scholar 

  52. Legrain V, Taieb A, Sage T, et al. Urticaria in infants: a study of forty patients. Pediatr Dermatol 1990; 7(2): 101–7

    Article  PubMed  CAS  Google Scholar 

  53. Ghosh S, Kanwar AJ, Kaur S. Urticaria in children. Pediatr Dermatol 1993; 10(2): 107–10

    Article  PubMed  CAS  Google Scholar 

  54. Mortureux P, Leaute-Labreze C, Legrain-Lifermann V, et al. Acute urticaria in infancy and early childhood: a prospective study. Arch Dermatol 1998; 134(3): 319–23

    Article  PubMed  CAS  Google Scholar 

  55. Sillevis Smitt JH, Kozel MMA. Pathofysiologie van urticaria en urticariele vasculitis. In: de Waard-van der Spek FB, Orangje AP, editors. Diagnostiek en therapie in de kinderdermatologie. Rotterdam: 8e cursus van de Nederlands Belgische Vereniging voor Kinderdermatologie, 2001: 83–90

    Google Scholar 

  56. Harris A, Twarog FJ, Geha RS. Chronic urticaria in childhood: natural course and etiology. Ann Allergy 1983; 51 (2 Pt 1): 161–5

    PubMed  CAS  Google Scholar 

  57. Volonakis M, Katsarou-Katsari A, Stratigos J. Etiologic factors in childhood chronic urticaria. Ann Allergy 1992; 69(1): 61–5

    PubMed  CAS  Google Scholar 

  58. Greaves MW. Chronic urticaria. N Engl J Med 1995; 332: 1767–72

    Article  PubMed  CAS  Google Scholar 

  59. Zuberbier T, Henz BM. Diagnosis of urticaria. In: Henz BM, Zuberbier T, Grabbe J, et al., editors. Urticaria: clinical, diagnostic and therapeutic aspects. Berlin: Springer Verlag, 1998: 18–38

    Google Scholar 

  60. Friedmann PS. Assessment of urticaria and angio-oedema. Clin Exp Allergy 1999; 29 Suppl. 3: 109–12

    Article  PubMed  Google Scholar 

  61. Bindslev-Lensen C, Finzi A, Greaves M, et al. Chronic urticaria: diagnostic recommendations. J Eur Acad Dermatol Venereol 2000; 14(3): 175–80

    Article  PubMed  CAS  Google Scholar 

  62. Grattan C, Powell S, Humphreys F. Management and diagnostic guidelines for urticaria and angio-oedema. Br J Dermatol 2001; 144(4): 708–14

    Article  PubMed  CAS  Google Scholar 

  63. Kozel MM, Mekkes JR, Bossuyt PM, et al. The effectiveness of a history-based diagnostic approach in chronic urticaria and angioedema. Arch Dermatol 1998; 134(12): 1575–80

    Article  PubMed  CAS  Google Scholar 

  64. Kozel MM, Moein MC, Mekkes JR, et al. Evaluation of a clinical guideline for the diagnoses of physical and chronic urticaria and angioedema. Acta Derm Venereol 2002; 82(4): 270–4

    Article  PubMed  Google Scholar 

  65. Questionnaire for patients with chronic urticaria (hives, wheals) and/or angioedema (deeply located swelling of the skin) [online]. Available from URL: www.huidziekten.nl/pdf/urticaria-questionnaire.pdf [Accessed 2004 Aug 19]

  66. Grattan CE, Sabroe RA, Greaves MW. Chronic urticaria. J Am Acad Dermatol 2002; 46(5): 645–57

    Article  PubMed  Google Scholar 

  67. Zuberbier T, Greaves MW, Juhlin L, et al. Management of urticaria: a consensus report. J Investig Dermatol Symp Proc 2001; 6(2): 128–31

    Article  PubMed  CAS  Google Scholar 

  68. Karim Y, Griffiths H, Deacock S. Normal complement C4 values do not exclude hereditary angioedema. J Clin Pathol 2004; 57(2): 213–4

    Article  PubMed  CAS  Google Scholar 

  69. O’Donnell B, Black AK. Urticarial vasculitis. Int Angiol 1995; 14(2): 166–74

    PubMed  Google Scholar 

  70. Urbach E. [Chapter title unknown]. In: Urbach E, Gottlieb PM, editors. Allergy. 2nd ed. New York: Grune and Stratton, 1946

  71. Juhlin L. Recurrent urticaria: clinical investigation of 330 patients. Br J Dermatol 1981; 104: 369–81

    Article  PubMed  CAS  Google Scholar 

  72. Quaranta JH, Rohr AS, Rachelefsky GS, et al. The natural history and response to therapy of chronic urticaria and angioedema. Ann Allergy 1989; 62(5): 421–4

    PubMed  CAS  Google Scholar 

  73. Champion RH, Roberts SOB, Carpenter RG, et al. Urticaria and angio-oedema: a review of 554 patients. Br J Dermatol 1969; 81: 588–97

    Article  PubMed  CAS  Google Scholar 

  74. van der Valk PG, Moret G, Kiemeney LA. The natural history of chronic urticaria and angioedema in patients visiting a tertiary referral centre. Br J Dermatol 2002; 146(1): 110–3

    Article  PubMed  Google Scholar 

  75. Kozel MM, Mekkes JR, Bossuyt PM, et al. Natural course of physical and chronic urticaria and angioedema in 220 patients. J Am Acad Dermatol 2001; 45(3): 387–91

    Article  PubMed  CAS  Google Scholar 

  76. Beattie PE, Dawe RS, Ibbotson SH, et al. Characteristics and prognosis of idiopathic solar urticaria: a cohort of 87 cases. Arch Dermatol 2003; 139(9): 1149–54

    Article  PubMed  Google Scholar 

  77. Finlay AY, Khan GK. Dermatology Life Quality Index (DLQI): a simple practical measure for routine clinical use. Clin Exp Dermatol 1994; 19(3): 210–6

    Article  PubMed  CAS  Google Scholar 

  78. Poon E, Seed PT, Greaves MW, et al. The extent and nature of disability in different urticarial conditions. Br J Dermatol 1999; 140: 667–71

    Article  PubMed  CAS  Google Scholar 

  79. O’Donnell BF, Lawlor F, Simpson J, et al. The impact of chronic urticaria on the quality of life. Br J Dermatol 1997; 136: 197–201

    Article  PubMed  Google Scholar 

  80. Baiardini I, Giardini A, Pasquali M, et al. Quality of life and patients’ satisfaction in chronic urticaria and respiratory allergy. Allergy 2003; 58(7): 621–3

    Article  PubMed  CAS  Google Scholar 

  81. Bromm B, Scharein E, Darsow U, et al. Effects of menthol and cold on histamine-induced itch and skin reactions in man. Neurosci Lett 1995; 187: 157–60

    Article  PubMed  CAS  Google Scholar 

  82. Lawlor F, Kobza Black A, Murdoch RD, et al. Symptomatic dermographism: wealing, mast cells and histamine are decreased in the skin following long-term application of a potent topical corticosteroid. Br J Dermatol 1989; 121: 629–34

    Article  PubMed  CAS  Google Scholar 

  83. Taylor JS, Praditsuwan P, Handel D, et al. Allergic contact dermatitis from doxepin cream: one-year patch test clinic experience. Arch Dermatol 1996; 132: 515–8

    Article  PubMed  CAS  Google Scholar 

  84. Humphreys F, Hunter JAA. The characteristics of urticaria in 390 patients. Br J Dermatol 1998; 138: 635–8

    Article  PubMed  CAS  Google Scholar 

  85. Nettis E, Pannofino A, D’Aprile C, et al. Clinical and aetiological aspects in urticaria an angio-oedema. Br J Dermatol 2003; 148: 501–6

    Article  PubMed  CAS  Google Scholar 

  86. Bleehen SS, Thomas SE, Greaves MW, et al. Cimetidine and chlorpheniramine in the treatment of chronic idiopathic urticaria: a multi-centre randomised double-blind study. Br J Dermatol 1987; 117(1): 81–8

    Article  PubMed  CAS  Google Scholar 

  87. Yosipovitch G, Ansari N, Goon A, et al. Clinical characteristics of pruritus in chronic idiopathic urticaria. Br J Dermatol 2002; 147: 32–6

    Article  PubMed  CAS  Google Scholar 

  88. Pearlman DS. Antihistamines: pharmacology and clinical use. Drugs 1976; 12(4): 258–73

    Article  PubMed  CAS  Google Scholar 

  89. Simons FER, Simons KJ. The pharmacology and use of H1-receptor-antagonist drugs. N Engl J Med 1994; 330(23): 1663–70

    Article  PubMed  CAS  Google Scholar 

  90. Haria M, Fitton A, Peters DH. Loratadine: a reappraisal of its pharmacological properties and therapeutic use in allergic disorders. Drugs 1994; 48(4): 617–37

    Article  PubMed  CAS  Google Scholar 

  91. Spencer CM, Faulds D, Peters DH. Cetirizine: a reappraisal of its pharmacological properties and therapeutic use in selected allergic disorders. Drugs 1993; 46(6): 1055–80

    Article  PubMed  CAS  Google Scholar 

  92. Brogden RN, McTavish D. Acrivastine: a review of its pharmacological properties and therapeutic efficacy in allergic rhinitis, urticaria and related disorders. Drugs 1991; 41(6): 927–40

    Article  PubMed  CAS  Google Scholar 

  93. Campoli-Richards DM, Buckley MMT, Fitton A. Cetirizine: a review of its pharmacological properties and clinical potential in allergic rhinitis, pollen-induced asthma, and chronic urticaria. Drugs 1990; 40(5): 762–81

    Article  PubMed  CAS  Google Scholar 

  94. Curran MP, Scott LJ, Perry CM. Cetirizine: a review of its use in allergic disorders. Drugs 2004; 64(5): 523–61

    Article  PubMed  CAS  Google Scholar 

  95. Slater JW, Zechnich AD, Haxby DG. Second-generation antihistamines: a comparative review. Drugs 1999; 57(1): 31–47

    Article  PubMed  CAS  Google Scholar 

  96. Walsh GM, Annunziato L, Frossard N, et al. New insights into the second-generation antihistamines. Drugs 2001; 61(2): 207–36

    Article  PubMed  CAS  Google Scholar 

  97. Ormerod AD. Urticaria: recognition, causes and treatment. Drugs 1994; 48(5): 717–30

    Article  PubMed  CAS  Google Scholar 

  98. Kaplan AP. Clinical practice: chronic urticaria and angioedema. N Engl J Med 2002; 346(3): 175–9

    Article  PubMed  Google Scholar 

  99. McClellan K, Jarvis B. Desloratadine. Drugs 2001; 61(6): 789–96

    Article  PubMed  CAS  Google Scholar 

  100. Murdoch D, Goa KL, Keam SJ. Desloratadine: an update of its efficacy in the management of allergic disorders. Drugs 2003; 63(19): 2051–77

    Article  PubMed  CAS  Google Scholar 

  101. Ring J, Hein R, Gauger A, et al. Once-daily desloratadine improves the signs and symptoms of chronic idiopathic urticaria: a randomized, double-blind, placebo-controlled study. Int J Dermatol 2001; 40(1): 72–6

    Article  PubMed  CAS  Google Scholar 

  102. Monroe E, Finn A, Patel P, et al. Efficacy and safety of desloratadine 5mg once daily in the treatment of chronic idiopathic urticaria: a double-blind, randomized, placebo-controlled trial. J Am Acad Dermatol 2003; 48(4): 535–41

    Article  PubMed  Google Scholar 

  103. Henz BM. The pharmacologic profile of desloratadine: a review. Allergy 2001; 56 Suppl. 65: 7–13

    Article  PubMed  Google Scholar 

  104. Simons FE. Comparative pharmacology of H1 antihistamines: clinical relevance. Am J Med 2002; 113 Suppl. 9A: 38S–46S

    Article  PubMed  CAS  Google Scholar 

  105. Geha RS, Meltzer EO. Desloratadine: a new, nonsedating, oral antihistamine. J Allergy Clin Immunol 2001; 107(4): 751–62

    Article  PubMed  CAS  Google Scholar 

  106. Taglialatela M, Pannaccione A, Castaldo P, et al. Molecular basis for the lack of HERG K+ channel block-related cardiotoxicity by the H1 receptor blocker cetirizine compared with other second-generation antihistamines. Mol Pharmacol 1998; 54(1): 113–21

    PubMed  CAS  Google Scholar 

  107. Simpson K, Jarvis B. Fexofenadine: a review of its use in the management of seasonal allergic rhinitis and chronic idiopathic urticaria. Drugs 2000; 59(2): 301–21

    Article  PubMed  CAS  Google Scholar 

  108. Rampe D, Wible B, Brown AM, et al. Effects of terfenadine and its metabolites on a delayed rectifier K+ channel cloned from human heart. Mol Pharmacol 1993; 44(6): 1240–5

    PubMed  CAS  Google Scholar 

  109. Pratt CM, Mason J, Russell T, et al. Cardiovascular safety of fexofenadine HC1. Am J Cardiol 1999; 83(10): 1451–4

    Article  PubMed  CAS  Google Scholar 

  110. Craig-McFeely PM, Acharya NV, Shakir SA. Evaluation of the safety of fexofenadine from experience gained in general practice use in England in 1997. Eur J Clin Pharmacol 2001; 57(4): 313–20

    Article  PubMed  CAS  Google Scholar 

  111. Pinto YM, van Gelder IC, Heeringa M, et al. QT lengthening and life-threatening arrhythmias associated with fexofenadine [letter]. Lancet 1999; 353(9157): 980

    Article  PubMed  CAS  Google Scholar 

  112. Paul E, Berth-Jones J, Ortonne J-P, et al. Fexofenadine hydrochloride in the treatment of chronic idiopathic urticaria: a placebo-controlled, parallel-group, dose-ranging study. J Dermatol Treat 1998; 9: 143–9

    Article  CAS  Google Scholar 

  113. Nelson HS, Reynolds R, Mason J. Fexofenadine HC1 is safe and effective for treatment of chronic idiopathic urticaria. Ann Allergy Asthma Immunol 2000; 84(5): 517–22

    Article  PubMed  CAS  Google Scholar 

  114. Banfield C, Gupta S, Marino M, et al. Grapefruit juice reduces the oral bioavailability of fexofenadine but not desloratadine. Clin Pharmacokinet 2002; 41(4): 311–8

    Article  PubMed  CAS  Google Scholar 

  115. Benedetti MS, Plisnier M, Kaise J, et al. Absorption, distribution, metabolism and excretion of [14C]levocetirizine, the R enantiomer of cetirizine, in healthy volunteers. Eur J Clin Pharmacol 2001; 57(8): 571–82

    Article  PubMed  CAS  Google Scholar 

  116. Medicines compendium 2003. Epsom, Surrey: Datapharm Communications Ltd in association with Virtual Health Network Ltd, 2003: 2365–6

  117. Lebrun-Vignes B, Diquet B, Chosidow O. Clinical pharmacokinetics of mizolastine. Clin Pharmacokinet 2001; 40(7): 501–7

    Article  PubMed  CAS  Google Scholar 

  118. Taglialatela M, Pannaccione A, Castaldo P, et al. Inhibition of HERG1 K (+) channels by the novel second-generation anti-histamine mizolastine. Br J Pharmacol 2000; 131(6): 1081–8

    Article  PubMed  CAS  Google Scholar 

  119. Chaufour S, Caplain H, Lilienthal N, et al. Study of cardiac repolarization in healthy volunteers performed with mizolastine, a new H1-receptor antagonist. Br J Clin Pharmacol 1999; 47(5): 515–20

    Article  PubMed  CAS  Google Scholar 

  120. Delauche-Cavallier MC, Chaufour S, Guerault E, et al. QT interval monitoring during clinical studies with mizolastine, a new H1 antihistamine. Clin Exp Allergy 1999; 29 Suppl. 3: 206–11

    Article  PubMed  CAS  Google Scholar 

  121. Dubertret L, Murrieta Aguttes M, Tonet J. Efficacy and safety of mizolastine 10mg in a placebo-controlled comparison with loratadine in chronic idiopathic urticaria: results of the MILOR Study. J Eur Acad Dermatol Venereol 1999; 12(1): 16–24

    Article  PubMed  CAS  Google Scholar 

  122. Lorette G, Giannetti A, Pereira RS, et al. One-year treatment of chronic urticaria with mizolastine: efficacy and safety. J Eur Acad Dermatol Venereol 2000; 14: 83–90

    Article  PubMed  CAS  Google Scholar 

  123. Grant JA, Riethuisen J-M, Moulaert B, et al. A double-blind, randomized, single-dose, crossover comparison of levoce-tirizine with ebastine, fexofenadine, loratadine, mizolastine, and placebo: suppression of histamine-induced wheal-and-flare response during 24 hours in healthy male subjects. Ann Allergy Asthma Immmunol 2002; 88: 190–7

    Article  CAS  Google Scholar 

  124. Rosenzweig P, Caplain H, Chaufour S, et al. Comparative wheal and flare study of mizolastine vs terfenadine, cetirizine, loratadine and placebo in healthy volunteers. Br J Clin Pharmacol 1995; 40(5): 459–65

    PubMed  CAS  Google Scholar 

  125. Purohit A, Melac M, Pauli G, et al. Comparative activity of cetirizine and mizolastine on histamine-induced skin wheal and flare responses at 24 h. Br J Pharmacol 2002; 53: 250–4

    Article  CAS  Google Scholar 

  126. Simons FE, Silver NA, Gu X, et al. Clinical pharmacology of H1-antihistamines in the skin. J Allergy Clin Immunol 2002; 110(5): 777–83

    Article  PubMed  CAS  Google Scholar 

  127. Thompson AK, Finn AF, Schoenwetter WF. Effect of 60mg twice-daily fexofenadine HC1 on quality of life, work and classroom productivity, and regular activity in patients with chronic idiopathic urticaria. J Am Acad Dermatol 2000; 43 (1 Pt 1): 24–30

    Article  PubMed  CAS  Google Scholar 

  128. Leynadier F, Duarte-Risselin C, Murrieta M. Comparative therapeutic effect and safety of mizolastine and loratadine in chronic idiopathic urticaria: URTILOR Study Group. Eur J Dermatol 2000; 10(3): 205–11

    PubMed  CAS  Google Scholar 

  129. Handa S, Dogra S, Kumar B. Comparative efficacy of cetirizine and fexofenadine in the treatment of chronic idiopathic urticaria. J Dermatol Treat 2004; 15(1): 55–7

    Article  CAS  Google Scholar 

  130. Devalia JL, De Vos C, Hanotte F, et al. A randomized, double-blind, crossover comparison among cetirizine, levocetirizine, and ucb 28557 on histamine-induced cutaneous responses in healthy adult volunteers. Allergy 2001; 56(1): 50–7

    Article  PubMed  CAS  Google Scholar 

  131. Mann RD, Pearce GL, Dunn N, et al. Sedation with ‘non-sedating’ antihistamines: four prescription-event monitoring studies in general practice. BMJ 2000; 320(7243): 1184–6

    Article  PubMed  CAS  Google Scholar 

  132. Hindmarch I, Shamsi Z, Kimber S. An evaluation of the effects of high-dose fexofenadine on the central nervous system: a double-blind, placebo-controlled study in healthy volunteers. Clin Exp Allergy 2002; 32(1): 133–9

    Article  PubMed  CAS  Google Scholar 

  133. Gandon JM, Allain H. Lack of effect of single and repeated doses of levocetirizine, a new antihistamine drug, on cognitive and psychomotor functions in healthy volunteers. Br J Clin Pharmacol 2002; 54(1): 51–8

    Article  PubMed  CAS  Google Scholar 

  134. Verster JC, Volkerts ER, van Oosterwijck AW, et al. Acute and subchronic effects of levocetirizine and diphenhydramine on memory functioning, psychomotor performance, and mood. J Allergy Clin Immunol 2003; 111(3): 623–7

    Article  PubMed  CAS  Google Scholar 

  135. Wakelin SH. Handbook of systemic drug treatment in dermatology. London: Manson Publishing, 2002: 70

    Google Scholar 

  136. Schatz M. Hl-antihistamines in pregnancy and lactation. Clin Allergy Immunol 2002; 17: 421–36

    PubMed  CAS  Google Scholar 

  137. Einarson A, Bailey B, Jung G, et al. Prospective controlled study of hydroxyzine and cetirizine in pregnancy. Ann Allergy Asthma Immunol 1997; 78(2): 183–6

    Article  PubMed  CAS  Google Scholar 

  138. Moretti ME, Caprara D, Coutinho CJ, et al. Fetal safety of loratadine use in the first trimester of pregnancy: a multicenter study. J Allergy Clin Immunol 2003; 111(3): 479–83

    Article  PubMed  CAS  Google Scholar 

  139. Diav-Citrin O, Shechtman S, Aharonovich A, et al. Pregnancy outcome after gestational exposure to loratadine or antihistamines: a prospective controlled cohort study. J Allergy Clin Immunol 2003; 111(6): 1239–43

    Article  PubMed  CAS  Google Scholar 

  140. Seto A, Einarson T, Koren G. Pregnancy outcome following first trimester exposure to antihistamines: meta-analysis. Am J Perinatal 1997; 14(3): 119–24

    Article  CAS  Google Scholar 

  141. Demoly P, Piette V, Daures JP. Treatment of allergic rhinitis during pregnancy. Drugs 2003; 63(17): 1813–20

    Article  PubMed  CAS  Google Scholar 

  142. Harvey RP, Wegs J, Schocket AL. A controlled trial of therapy in chronic urticaria. J Allergy Clin Immunol 1981; 68(4): 262–6

    Article  PubMed  CAS  Google Scholar 

  143. Mansfield LE, Smith JA, Nelson HS. Greater inhibition of dermographia with a combination of H1 and H2 antagonists. Ann Allergy 1983; 50(4): 264–5

    PubMed  CAS  Google Scholar 

  144. Monroe EW, Cohen SH, Kalbfleisch J, et al. Combined H1 and H2 antihistamine therapy in chronic urticaria. Arch Dermatol 1981; 117(7): 404–7

    Article  PubMed  CAS  Google Scholar 

  145. Kaur S, Greaves M, Eftekhari N. Factitious urticaria (dermogra-phism): treatment by cimetidine and chlorpheniramine in a randomized double-blind study. Br J Dermatol 1981; 104(2): 185–90

    Article  PubMed  CAS  Google Scholar 

  146. Paul E, Bodeker RH. Treatment of chronic urticaria with terfenadine and ranitidine: a randomized double-blind study in 45 patients. Eur J Clin Pharmacol 1986; 31(3): 277–80

    Article  PubMed  CAS  Google Scholar 

  147. Moscati RM, Moore GP. Comparison of cimetidine and diphenhydramine in the treatment of acute urticaria. Ann Emerg Med 1990; 19(1): 12–5

    Article  PubMed  CAS  Google Scholar 

  148. Cook LJ, Shuster S. Lack of effect of cimetidine in chronic idiopathic urticaria. Acta Derm Venereol 1983; 63(3): 265–7

    PubMed  CAS  Google Scholar 

  149. Sharpe GR, Shuster S. In dermographic urticaria H2 receptor antagonists have a small but therapeutically irrelevant additional effect compared with H1 antagonists alone. Br J Dermatol 1993; 129(5): 575–9

    Article  PubMed  CAS  Google Scholar 

  150. Simons FE, Sussman GL, Simons KJ. Effect of the H2-antagonist cimetidine on the pharmacokinetics and pharmacodynamics of the H1-antagonists hydroxyzine and cetirizine in patients with chronic urticaria. J Allergy Clin Immunol 1995; 95(3): 685–93

    Article  PubMed  CAS  Google Scholar 

  151. Greene SL, Reed CE, Schroeter AL. Double-blind crossover study comparing doxepin with diphenhydramine for the treatment of chronic urticaria. J Am Acad Dermatol 1985; 12(4): 669–75

    Article  PubMed  CAS  Google Scholar 

  152. Harto A, Sendagorta E, Ledo A. Doxepin in the treatment of chronic urticaria. Dermatologica 1985; 170(2): 90–3

    Article  PubMed  CAS  Google Scholar 

  153. Neittaanmaki H, Myohanen T, Fraki JE. Comparison of cinnarizine, cyproheptadine, doxepin, and hydroxyzine in treatment of idiopathic cold urticaria: usefulness of doxepin. J Am Acad Dermatol 1984; 11(3): 483–9

    Article  PubMed  CAS  Google Scholar 

  154. Furukawa T, McGuire H, Barbui C. Low dosage tricyclic anti-depressants for depression. Cochrane Database Syst Rev 2003; (3): CD003197

  155. Norris JG, Sullivan TJ. Leukotrienes and cytokines in steroid dependent chronic urticaria [abstract]. J Allergy Clin Immunol 1998; 101 (1 Pt 2): S128

    Article  Google Scholar 

  156. Chu TJ, Warren MS. Zafirlukast (ACCOLATE®) in the treatment of chronic idiopathic urticaria: a case series [abstract]. J Allergy Clin Immunol 1998; 101 (1 Pt 2): S155

    Google Scholar 

  157. Nettis E, Dambra P. Comparison of montelukast and fexofenadine for chronic idiopathic urticaria. Arch Dermatol 2001; 137: 99–100

    PubMed  CAS  Google Scholar 

  158. Bensch G, Borish L. Leukotriene modifiers in chronic urticaria. Ann Allergy Asthma Immmunol 1999; 83(4): 348

    Article  CAS  Google Scholar 

  159. Berkun Y, Shalit M. Successful treatment of delayed pressure urticaria with montelukast. Allergy 2000; 55(2): 203–4

    Article  PubMed  CAS  Google Scholar 

  160. Zulal E. The leukotriene receptor antagonist montelukast in the treatment of chronic idiopathic urticaria: a single blind, placebo-controlled, crossover clinical study. J Allergy Clin Immunol 2002; 110(3): 484–8

    Article  CAS  Google Scholar 

  161. Bagenstose SE, Levin L, Bernstein JA. The addition of zafirlukast to cetirizine improves the treatment of chronic urticaria in patients with positive autologous serum skin test results. J Allergy Clin Immunol 2004; 113(1): 134–40

    Article  PubMed  CAS  Google Scholar 

  162. Pacor ML, Di Lorenzo G, Corrocher R. Efficacy of leukotriene receptor antagonist in chronic urticaria: a double-blind, placebo-controlled comparison of treatment with montelukast and cetirizine in patients with chronic urticaria with intolerance to food additive and/or acetylsalicylic acid. Clin Exp Allergy 2001; 31: 1607–14

    Article  PubMed  CAS  Google Scholar 

  163. Reimers A, Pichler C, Helbling A, et al. Zafirlukast has no beneficial effects in the treatment of chronic urticaria. Clin Exp Allergy 2002; 32(12): 1763–8

    Article  PubMed  CAS  Google Scholar 

  164. Ohnishi-Inoue Y, Mitsuya K, Horio T. Aspirin-sensitive urticaria: provocation with a leukotriene receptor antagonist. Br J Dermatol 1998; 138: 483–5

    Article  PubMed  CAS  Google Scholar 

  165. Minciullo PL, Saija A, Bonanno D, et al. Montelukast-induced generalized urticaria. Ann Pharmacother 2004; 38(6): 999–1001

    Article  PubMed  Google Scholar 

  166. Zuberbier T, Iffländer J, Semmler C, et al. Acute urticaria: clinical aspects and therapeutic responsiveness. Acta Derm Venereol (Stockh) 1996; 76: 295–7

    CAS  Google Scholar 

  167. Greaves M. Chronic urticaria. J Allergy Clin Immunol 2000; 105(4): 664–72

    Article  PubMed  CAS  Google Scholar 

  168. Black AK, Greaves MW. Antihistamines in urticaria and angioedema. Clin Allergy Immunol 2002; 17: 249–86

    PubMed  CAS  Google Scholar 

  169. Kaplan AP. Urticaria and angioedema. In: Kaplan AP, editor. Allergy. New York: Churchill Livingstone, 1985: 439

    Google Scholar 

  170. Henz BM, Zuberbier T, Monroe E. Urticaria therapy. In: Henz BM, Zuberbier T, Grabbe J, et al., editors. Urticaria: clinical, diagnostic and therapeutic aspects. Berlin: Springer Verlag, 1998:161–81

    Google Scholar 

  171. Nesbitt LT. Glucocorticoids. In: Bologna JL, Jorizzo JL, Rapini RP, editors. Dermatology. London: Mosby, 2003: 1979–89

    Google Scholar 

  172. Guidelines Working Group for the Bone and Tooth Society. Glucocorticoid-induced osteoporosis: guidelines for prevention and treatment. London: National Osteoporosis Society and Royal College of Physicians, 2002

    Google Scholar 

  173. Barlow RJ, Kobza Black A, Greaves MW. Treatment of severe, chronic urticaria with cyclosporin A. Eur J Dermatol 1993; 3: 273–5

    Google Scholar 

  174. Grattan CEH, O’Donnell BF, Francis DM, et al. Randomized double-blind study of cyclosporin in chronic idiopathic urticaria. Br J Dermatol 2000; 143: 365–72

    Article  PubMed  CAS  Google Scholar 

  175. Grattan CEH, Kobza Black A. Urticaria and angioedema. In: Bologna JL, Jorizzo JL, Rapini RP, editors. Dermatology. London: Mosby, 2003: 287–302

    Google Scholar 

  176. Stanaland BE. Treatment of patients with chronic idiopathic urticaria. Clin Rev Allergy Immunol 2002; 23(2): 233–41

    Article  PubMed  CAS  Google Scholar 

  177. Sabroe RA, Glendinning AK, Sabroe I, et al. An audit of the use of self-administered adrenaline syringes in patients with angiooedema. Br J Dermatol 2002; 146(4): 615–20

    Article  PubMed  CAS  Google Scholar 

  178. O’Donnell BF, Barr RM, Kobza Black A, et al. Intravenous immunoglobulin in autoimmune chronic urticaria. Br J Dermatol 1998; 138: 101–6

    Article  PubMed  Google Scholar 

  179. Kroiss M, Vogt T, Landthaler M, et al. The effectiveness of low-dose intravenous immunoglobulins in chronic urticaria [letter]. Acta Derm Venereol 2000; 80(3): 225

    Article  PubMed  CAS  Google Scholar 

  180. Asero R. Are IVIG for chronic unremitting urticaria effective? Allergy 2000; 55(11): 1099–101

    Article  PubMed  CAS  Google Scholar 

  181. Dalakas MC, Illa I, Dambrosia JM, et al. A controlled trial of high-dose intravenous immune globulin infusions as treatment for dermatomyositis. N Engl J Med 1993; 329(27): 1993–2000

    Article  PubMed  CAS  Google Scholar 

  182. Grattan CEH, Francis DM, Slater NGP, et al. Plasmapheresis for severe, unremitting, chronic urticaria. Lancet 1992; 339: 1078–80

    Article  PubMed  CAS  Google Scholar 

  183. Jaffer AM. Sulfasalazine in the treatment of corticosteroid-dependent chronic idiopathic urticaria. J Allergy Clin Immunol 1991; 88(6): 964–5

    Article  PubMed  CAS  Google Scholar 

  184. Hartmann K, Hani N, Hinrichs R, et al. Successful sulfasalazine treatment of severe chronic idiopathic urticaria associated with pressure urticaria [letter]. Acta Derm Venereol 2001; 81(1): 71

    Article  PubMed  CAS  Google Scholar 

  185. Engler RJ, Squire E, Benson P. Chronic sulfasalazine therapy in the treatment of delayed pressure urticaria and angioedema. Ann Allergy Asthma Immunol 1995; 74(2): 155–9

    PubMed  CAS  Google Scholar 

  186. Gach JE, Sabroe RA, Greaves MW, et al. Methotrexate-responsive chronic idiopathic urticaria: a report of two cases. Br J Dermatol 2001; 145: 340–3

    Article  PubMed  CAS  Google Scholar 

  187. Bernstein JA, Garramone SM, Lower EG. Successful treatment of autoimmune chronic idiopathic urticaria with intravenous cyclophosphamide. Ann Allergy Asthma Immunol 2002; 89(2): 212–4

    Article  PubMed  Google Scholar 

  188. Donaldson VH, Bernstein DI, Wagner CJ, et al. Angioneurotic edema with acquired C1-inhibitor deficiency and autoantibody to C1-inhibitor: response to plasmapheresis and cytotoxic therapy. J Lab Clin Med 1992; 119(4): 397–406

    PubMed  CAS  Google Scholar 

  189. Parsad D, Pandhi R, Juneja A. Stanozolol in chronic urticaria: a double blind, placebo controlled trial. J Dermatol 2001; 28(6): 299–302

    PubMed  CAS  Google Scholar 

  190. Brestel EP, Thrush LB. The treatment of glucocorticosteroid-dependent chronic urticaria with stanozolol. J Allergy Clin Immunol 1988; 82(2): 265–9

    Article  PubMed  CAS  Google Scholar 

  191. Boehncke WH, Ludwig RJ, Zollner TM, et al. The selective cyclooxygenase-2 inhibitor rofecoxib may improve the treatment of chronic idiopathic urticaria. Br J Dermatol 2003; 148(3): 604–6

    Article  PubMed  CAS  Google Scholar 

  192. Anand MK, Nelson HS, Dreskin SC. A possible role for cyclo-oxygenase 2 inhibitors in the treatment of chronic urticaria. J Allergy Clin Immunol 2003; 111(5): 1133–6

    Article  PubMed  Google Scholar 

  193. Demera RS, Ryhal B, Gershwin ME. Chronic idiopathic urticaria. Compr Ther 2001; 27(3): 213–7

    Article  PubMed  CAS  Google Scholar 

  194. Tharp MD. Chronic urticaria: pathophysiology and treatment approaches. J Allergy Clin Immunol 1996; 98 (6 Pt 3): S325–30

    PubMed  CAS  Google Scholar 

  195. Boehm I, Bauer R, Bieber T. Urticaria treated with dapsone. Allergy 1999; 54(7): 765–6

    Article  PubMed  CAS  Google Scholar 

  196. Reeves GE, Boyle MJ, Bonfield J, et al. Impact of hydroxychloroquine therapy on chronic urticaria: chronic autoimmune urticaria study and evaluation. Intern Med J 2004; 34(4): 182–6

    Article  PubMed  CAS  Google Scholar 

  197. Sharma JK, Miller R, Murray S. Chronic urticaria: a Canadian perspective on patterns and practical management strategies. J Cutan Med Surg 2000; 4(2): 89–93

    PubMed  CAS  Google Scholar 

  198. Berroeta L, Clark C, Ibbotson SH, et al. Narrow-band (TL-01) ultraviolet B phototherapy for chronic urticaria [letter]. Clin Exp Dermatol 2004; 29(1): 97–8

    Article  PubMed  CAS  Google Scholar 

  199. Logan RA, O’Brien TJ, Greaves MW. The effect of psoralen photochemotherapy (PUVA) on symptomatic dermographism. Clin Exp Dermatol 1989; 14(1): 25–8

    Article  PubMed  CAS  Google Scholar 

  200. Johnsson M, Falk ES, Volden G. UVB treatment of factitious urticaria. Photodermatol 1987; 4(6): 302–4

    PubMed  CAS  Google Scholar 

  201. Sussman GL, Harvey RP, Schocket AL. Delayed pressure urticaria. J Allergy Clin Immunol 1982; 70(5): 337–42

    Article  PubMed  CAS  Google Scholar 

  202. Dover JS, Black AK, Ward AM, et al. Delayed pressure urticaria: clinical features, laboratory investigations, and response to therapy of 44 patients. J Am Acad Dermatol 1988; 18(6): 1289–98

    Article  PubMed  CAS  Google Scholar 

  203. Schocket AL. Physical urticarias. In: Schocket AL, editor. Clinical management of urticaria and anaphylaxis. New York: Marcel Dekker Inc., 1993: 69–98

    Google Scholar 

  204. Barlow RJ, Macdonald DM, Black AK, et al. The effects of topical corticosteroids on delayed pressure urticaria. Arch Dermatol Res 1995; 287(3–4): 285–8

    Article  PubMed  CAS  Google Scholar 

  205. Dayani A, Gould DJ, Campbell S. Delayed pressure urticaria, treatment with dapsone. J Dermatol Treat 1992; 3: 61–2

    Article  Google Scholar 

  206. Nettis E, Pannofino A, Cavallo E, et al. Efficacy of montelukast, in combination with loratadine, in the treatment of delayed pressure urticaria. J Allergy Clin Immunol 2003; 112(1): 212–3

    Article  PubMed  Google Scholar 

  207. Lawlor F, Black AK, Ward AM, et al. Delayed pressure urticaria, objective evaluation of a variable disease using a dermographometer and assessment of treatment using colchicine. Br J Dermatol 1989; 120(3): 403–8

    Article  PubMed  CAS  Google Scholar 

  208. Dawn G, Urcelay M, Ah-Weng A, et al. Effect of high-dose intravenous immunoglobulin in delayed pressure urticaria. Br J Dermatol 2003; 149(4): 836–40

    Article  PubMed  CAS  Google Scholar 

  209. Zuberbier T, Aberer W, Burtin B, et al. Efficacy of cetirizine in cholinergic urticaria. Acta Derm Venereol 1995; 75(2): 147–9

    PubMed  CAS  Google Scholar 

  210. Wong E, Eftekhari N, Greaves MW, et al. Beneficial effects of danazol on symptoms and laboratory changes in cholinergic urticaria. Br J Dermatol 1987; 116(4): 553–6

    Article  PubMed  CAS  Google Scholar 

  211. Juhlin L. Inhibition of cold urticaria by desloratadine. J Dermatolog Treat 2004; 15(1): 51–9

    Article  PubMed  CAS  Google Scholar 

  212. St-Pierre JP, Kobric M, Rackham A. Effect of ketotifen treatment on cold-induced urticaria. Ann Allergy 1985; 55(6): 840–3

    PubMed  CAS  Google Scholar 

  213. Black AK, Keahey TM, Eady RA, et al. Dissociation of histamine release and clinical improvement following treatment of acquired cold urticaria by prednisone. Br J Clin Pharmacol 1981; 12(3): 327–31

    Article  PubMed  CAS  Google Scholar 

  214. Marsland AM, Beck MH. Cold urticaria responding to systemic ciclosporin. Br J Dermatol 2003; 149(1): 214–5

    Article  PubMed  CAS  Google Scholar 

  215. Hani N, Hartmann K, Casper C, et al. Improvement of cold urticaria by treatment with the leukotriene receptor antagonist montelukast [letter]. Acta Derm Venereol 2000; 80(3): 229

    Article  PubMed  CAS  Google Scholar 

  216. Bonadonna P, Lombardi C, Senna G, et al. Treatment of acquired cold urticaria with cetirizine and zafirlukast in combination. J Am Acad Dermatol 2003; 49(4): 714–6

    Article  PubMed  Google Scholar 

  217. Ormerod AD, Smart L, Reid TM, et al. Familial cold urticaria: investigation of a family and response to stanozolol. Arch Dermatol 1993; 129(3): 343–6

    Article  PubMed  CAS  Google Scholar 

  218. Henquet CJM, Martens BPM, van Vloten WA. Cold urticaria: a clinico-therapeutic study in 30 patients; with special emphasis on cold desensitization. Eur J Dermatol 1992; 2: 75–7

    Google Scholar 

  219. Ryckaert S, Roelandts R. Solar urticaria: a report of 25 cases and difficulties in phototesting. Arch Dermatol 1998; 134(1): 71–4

    Article  PubMed  CAS  Google Scholar 

  220. Bilsland D, Ferguson J. A comparison of cetirizine and terfenadine in the management of solar urticaria. Photodermatol Photoimmunol Photomed 1991; 8(2): 62–4

    PubMed  CAS  Google Scholar 

  221. Neittaanmaki H, Jaaskelainen T, Harvima RJ, et al. Solar urticaria: demonstration of histamine release and effective treatment with doxepin. Photodermatol 1989; 6(1): 52–5

    PubMed  CAS  Google Scholar 

  222. Mekkes JR, de Vries HJ, Kammeyer A. Solar urticaria induced by infrared radiation. Clin Exp Dermatol 2003; 28(2): 222–3

    Article  PubMed  CAS  Google Scholar 

  223. Edstrom DW, Ros AM. Cyclosporin A therapy for severe solar urticaria. Photodermatol Photoimmunol Photomed 1997; 13(1-2): 61–3

    Article  PubMed  CAS  Google Scholar 

  224. Duschet P, Leyen P, Schwarz T, et al. Solar urticaria: effective treatment by plasmapheresis. Clin Exp Dermatol 1987; 12(3): 185–8

    Article  PubMed  CAS  Google Scholar 

  225. Leenutaphong V, Holzle E, Plewig G, et al. Plasmapheresis in solar urticaria. Dermatologica 1991; 182(1): 35–8

    Article  PubMed  CAS  Google Scholar 

  226. Ellis MH. Successful treatment of chronic urticaria with leukotriene antagonists. J Allergy Clin Immunol 1998; 102(5): 876–7

    Article  PubMed  CAS  Google Scholar 

  227. Spector S, Tan RA. Antileukotrienes in chronic urticaria [letter]. J Allergy Clin Immunol 1998; 101 (4 Pt 1): 572

    Article  PubMed  CAS  Google Scholar 

  228. Frieling U, Luger TA. Mycophenolate mofetil and leflunomide: promising compounds for the treatment of skin diseases. Clin Exp Dermatol 2002; 27(7): 562–70

    Article  PubMed  CAS  Google Scholar 

  229. Cohen S, Cannon GW, Schiff M, et al. Two-year, blinded, randomized, controlled trial of treatment of active rheumatoid arthritis with leflunomide compared with methotrexate. Arthritis Rheum 2001; 44(9): 1984–92

    Article  PubMed  CAS  Google Scholar 

  230. Scott DL, Smolen JS, Kalden JR, et al. Treatment of active rheumatoid arthritis with leflunomide: two year follow up of a double blind, placebo controlled trial versus sulfasalazine. Ann Rheum Dis 2001; 60: 913–23

    Article  PubMed  CAS  Google Scholar 

  231. Williams JD, Griffiths CE. Cytokine blocking agents in dermatology. Clin Exp Dermatol 2002; 27(7): 585–90

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgements

Both authors declare that there is no conflict of interest directly relevant to the contents of the manuscript and no funding was received for the preparation of this manuscript.

Author information

Authors and Affiliations

  1. Department of Dermatology, Red Cross Hospital, PO Box 1074, 1940 EB, Beverwijk, The Netherlands

    Martina M. A. Kozel

  2. Department of Dermatology, Barnsley District General Hospital, Barnsley, UK

    Ruth A. Sabroe

Authors
  1. Martina M. A. Kozel
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ruth A. Sabroe
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Martina M. A. Kozel.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Kozel, M.M.A., Sabroe, R.A. Chronic Urticaria. Drugs 64, 2515–2536 (2004). https://doi.org/10.2165/00003495-200464220-00003

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00003495-200464220-00003

Keywords

Search

Navigation